Taken together, although clinical data suggest a tumour-suppressive role of DUSP26, the majority of the experimental data instead suggest that DUSP26 antagonises p53-mediated cell death and promotes the dedifferentiated state typical of aggressive NB. Here, TP53 is linked to neoplasm.